In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and alzheimer disease

Archives of Neurology

Volumn 68, Issue 7, 2011, Pages 905-912

  Villemagne, Victor L ^a,b   Okamura, Nobuyuki ^c   Pejoska, Svetlana ^a   Drago, John ^b   Mulligan, Rachel S ^a   Chételat, Gaël ^a,d   Ackermann, Uwe ^a   O'Keefe, Graeme ^a   Jones, Gareth ^a   Gong, Sylvia ^a   Tochon Danguy, Henry ^a   Kung, Hank F ^e   Masters, Colin L ^b   Skovronsky, Daniel M ^e,f   Rowe, Christopher C ^a  

^a AUSTIN HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITÉ DE CAEN   (France)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f AVID RADIOPHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENSERAZIDE; CARBIDOPA PLUS LEVODOPA; CHOLINESTERASE INHIBITOR; FLORBENAZINE F 18; GINKGO BILOBA EXTRACT; LEVODOPA; PRAMIPEXOLE; RISPERIDONE; SELEGILINE; VESICULAR MONOAMINE TRANSPORTER 2;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; IN VIVO STUDY; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; STRIATONIGRAL DEGENERATION; VISUAL CORTEX;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AREA UNDER CURVE; BRAIN MAPPING; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; ROC CURVE; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 79960197365     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2011.142     Document Type: Article

References (50)

1. Masters CL, Cappai R, Barnham KJ, Villemagne VL. Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem. 2006;97(6):1700-1725. (Pubitemid 43873662)
2. McKeith IG, Dickson DW, Lowe J, et al; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium [published correction appears in Neurology. 2005;65(12):1992]. Neurology. 2005;65(12):1863-1872. (Pubitemid 43970103)
3. Maetzler W, Liepelt I, Reimold M, et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis. 2009;34(1):107-112.
4. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008;71(12):903-910.
5. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry. 2008;79(12):1331-1338.
6. Rowe CC, Ng S, Ackermann U, et al. Imaging β-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718-1725. (Pubitemid 46763260)
7. McKeith IG, Mosimann UP. Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat Disord. 2004;10(suppl 1):S15-S18. (Pubitemid 38510425)
8. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP. Epidemiology of Parkinson's disease. J Neurol. 2008;255(suppl 5):18-32.
9. Brooks DJ. Imaging approaches to Parkinson disease. J Nucl Med. 2010;51(4):596-609.
10. Kemp PM, Holmes C. Imaging in dementia with Lewy bodies: a review. Nucl Med Commun. 2007;28(7):511-519. (Pubitemid 46848642)
11. Nirenberg MJ, Chan J, Liu Y, Edwards RH, Pickel VM. Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J Neurosci. 1996;16(13):4135-4145. (Pubitemid 26192409)
12. Ravina B, Eidelberg D, Ahlskog JE, et al. The role of radiotracer imaging in Parkinson disease. Neurology. 2005;64(2):208-215.
13. Frey KA, Koeppe RA, Kilbourn MR. Imaging the vesicular monoamine transporter. Adv Neurol. 2001;86:237-247.
14. 11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement. 2008;4(1)(suppl 1):S67-S76.
15. Gilman S, Koeppe RA, Little R, et al. Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Ann Neurol. 2004;55(6):774-780. (Pubitemid 38702572)
16. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab. 2006;26(9):1198-1212. (Pubitemid 44268182)
17. Frey KA, Koeppe RA, Kilbourn MR, et al. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol. 1996;40(6):873-884. (Pubitemid 27044605)
18. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol. 2000;47(4):493-503. (Pubitemid 30194606)
19. Martin WRW, Wieler M, Stoessl AJ, Schulzer M. Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. Ann Neurol. 2008;63(3):388-394. (Pubitemid 351499868)
20. 18F-FDG PET measures in differentiating dementias. J Nucl Med. 2005;46(6):936-944.
21. Chen M-K, Kuwabara H, Zhou Y, et al. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. J Neurochem. 2008;105(1):78-90. (Pubitemid 351441627)
22. Kung M-P, Hou C, Goswami R, Ponde DE, Kilbourn MR, Kung HF. Characterization of optically resolved 9-fluoropropyl-dihydrotetrabenazine as a potential PET imaging agent targeting vesicular monoamine transporters. Nucl Med Biol. 2007;34(3):239-246. (Pubitemid 46441853)
23. Goswami R, Ponde DE, Kung M-P, Hou C, Kilbourn MR, Kung HF. Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters. Nucl Med Biol. 2006;33(6):685-694. (Pubitemid 44247731)
24. 18F-AV-133: a selective VMAT2-binding radiopharmaceutical for PET imaging. PET Clin. 2010;5(1):75-82.
25. 18F-AV-133. J Nucl Med. 2010;51(2):223-228.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34(7):939-944.
27. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47(5):1113-1124. (Pubitemid 26374873)
28. McKeith IG, Ince P, Jaros EB, et al. What are the relations between Lewy body disease and AD? J Neural Transm Suppl. 1998;54:107-116. (Pubitemid 28539347)
29. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord. 2003;18(12):1415-1423. (Pubitemid 38035363)
30. O'Brien JT. Role of imaging techniques in the diagnosis of dementia. Br J Radiol. 2007;80(spec No. 2):S71-S77. (Pubitemid 351799333)
31. 18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol. 2005;191(suppl 1):S95-S103.
32. Ishii K, Imamura T, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease. Neurology. 1998;51(1):125-130. (Pubitemid 28345371)
33. 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 2008;49(3):390-398.
34. Imamura T, Ishii K, Sasaki M, et al. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Neurosci Lett. 1997;235(1-2):49-52. (Pubitemid 27471102)
35. 123I-β-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med. 2009;50(10):1638-1645.
36. Kono AK, Ishii K, Sofue K, Miyamoto N, Sakamoto S, Mori E. Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer's disease using FDG-PET and 3D-SSP. Eur J Nucl Med Mol Imaging. 2007;34(9):1490-1497. (Pubitemid 47312586)
37. Tatsch K. Imaging of the dopaminergic system in differential diagnosis of dementia. Eur J Nucl Med Mol Imaging. 2008;35(suppl 1):S51-S57.
38. Ishii K, Hosaka K, Mori T, Mori E. Comparison of FDG-PET and IMP-SPECT in patients with dementia with Lewy bodies. Ann Nucl Med. 2004;18(5):447-451. (Pubitemid 39265067)
39. Vander Borght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol. 1995;294(2-3):577-583. (Pubitemid 26016763)
40. 11C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse. 2008;62(11):873-876.
41. Suzuki M, Desmond TJ, Albin RL, Frey KA. Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. Ann Neurol. 2002;51(6):767-771. (Pubitemid 34568857)
42. Miller GW, Erickson JD, Perez JT, et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol. 1999;156(1):138-148. (Pubitemid 29152991)
43. Nikolaus S, Antke C, Müller H-W. In vivo imaging of synaptic function in the central nervous system, I: movement disorders and dementia. Behav Brain Res. 2009;204(1):1-31.
44. Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine. J Cereb Blood Flow Metab. 1999;19(12):1376-1384. (Pubitemid 30013629)
45. Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol. 2004;17(3):137-145. (Pubitemid 39128223)
46. Hashimoto M, Masliah E. Cycles of aberrant synaptic sprouting and neurodegeneration in Alzheimer's and dementia with Lewy bodies. Neurochem Res. 2003;28(11):1743-1756. (Pubitemid 37296216)
47. Masliah E, Rockenstein E, Veinbergs I, et al. β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A. 2001; 98(21):12245-12250. (Pubitemid 32959858)
48. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov Disord. 2001;16(4):622-630. (Pubitemid 36040841)
49. Iranzo A, Lomeña F, Stockner H, et al; Sleep Innsbruck Barcelona (SINBAR) Group. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eyemovement sleep behaviour disorder: a prospective study [published correction appears in Lancet Neurol. 2010;9(11):1045]. Lancet Neurol. 2010;9(11):1070-1077.
50. Walker Z, Jaros E, Walker RWH, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78(11):1176-1181. (Pubitemid 350057277)